Repatha (Evolocumab) Complete Drug-Drug Interaction Profile

How Evolocumab Works: Why Drug Interactions Are Rare

Evolocumab binds circulating PCSK9 protein and prevents it from degrading LDL receptors on hepatocyte surfaces. More LDL receptors survive, more LDL-C gets cleared from the bloodstream. The result: LDL-C reductions of 55% to 75% when added to statin therapy, as demonstrated in the FOURIER trial (N=27,564) [1].

Monoclonal Antibody Clearance Pathway

Small-molecule drugs pass through cytochrome P450 enzymes in the liver. Evolocumab does not. As a 144-kDa IgG2 monoclonal antibody, it undergoes proteolytic catabolism through the reticuloendothelial system, the same pathway that degrades endogenous immunoglobulins [2]. This distinction matters: CYP1A2, CYP2C9, CYP2D6, CYP3A4, and every other P450 isoform are irrelevant to evolocumab clearance.

Target-Mediated Drug Disposition

Evolocumab also clears through target-mediated drug disposition (TMDD). PCSK9 binding leads to internalization and lysosomal degradation of the antibody-antigen complex. At therapeutic doses, the non-specific proteolytic pathway dominates clearance, giving evolocumab predictable linear pharmacokinetics at the approved 140 mg Q2W and 420 mg QM doses [3].

Clinical Consequence

Because no hepatic enzymes, renal transporters, or drug efflux pumps participate in evolocumab metabolism, the theoretical basis for CYP-mediated or transporter-mediated interactions is absent. The FDA label states that "no formal drug interaction studies have been performed" precisely because the mechanism does not warrant them [2].

Evolocumab and Statins: The Most Common Co-Prescription

Nearly every patient on evolocumab is also taking a statin. This is by design. The FOURIER trial enrolled patients already on moderate- or high-intensity statin therapy and added evolocumab on top [1].

Pharmacokinetic Evidence

Population pharmacokinetic modeling from over 5,000 patients in the evolocumab clinical program found that co-administration with atorvastatin, rosuvastatin, or simvastatin did not alter evolocumab exposure (AUC or Cmax) [3]. Statins are CYP3A4 or CYP2C9 substrates; evolocumab does not inhibit or induce either enzyme.

Pharmacodynamic Interaction: Additive, Not Antagonistic

Statins upregulate both LDL receptor expression and PCSK9 secretion. The statin-induced rise in PCSK9 partially offsets the LDL receptor upregulation. Evolocumab neutralizes that excess PCSK9, allowing the full benefit of statin-driven receptor upregulation to manifest [4]. This is a beneficial pharmacodynamic combination, not a harmful interaction.

High-Intensity Statin + Evolocumab: What to Expect

In FOURIER, patients on high-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) who added evolocumab achieved median LDL-C of 30 mg/dL, a 59% reduction from baseline [1]. There was no increase in myopathy, hepatotoxicity, or new-onset diabetes attributable to the combination beyond what each drug produces alone.

Evolocumab and Ezetimibe

Ezetimibe inhibits intestinal cholesterol absorption via the NPC1L1 transporter. It is glucuronidated (UGT enzymes), not oxidized by CYP450 [5]. Evolocumab's proteolytic clearance and ezetimibe's UGT-dependent metabolism share no enzymatic overlap.

Triple Therapy Outcomes

In the RUTHERFORD-2 trial, patients on statin plus ezetimibe who added evolocumab achieved an additional 41% LDL-C reduction compared with placebo [6]. Adverse event rates in the triple-therapy subgroup did not differ from the statin-plus-evolocumab group.

Practical Guidance

No dose adjustment is required for either drug. Clinicians commonly add evolocumab when maximally tolerated statin plus ezetimibe still leaves LDL-C above target, particularly in patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) [7].

Evolocumab and Anticoagulants

Warfarin and direct oral anticoagulants (DOACs) are among the most interaction-prone drug classes. Warfarin is metabolized by CYP2C9 (S-warfarin) and CYP1A2/CYP3A4 (R-warfarin). Apixaban and rivaroxaban are CYP3A4 and P-glycoprotein substrates.

Warfarin

The FDA-approved evolocumab label reports no effect on warfarin pharmacokinetics or INR [2]. Because evolocumab does not interact with any CYP isoform, this outcome is predictable and consistent across published post-marketing data.

Direct Oral Anticoagulants

No dedicated PK studies exist for evolocumab plus apixaban, rivaroxaban, edoxaban, or dabigatran. The absence of CYP3A4 inhibition or P-gp modulation by evolocumab means no mechanistic basis for interaction exists. Post-marketing pharmacovigilance through 2024 has not identified safety signals for this combination [8].

What Clinicians Should Monitor

Standard anticoagulation monitoring (INR for warfarin, renal function for DOACs) applies. Evolocumab does not change these protocols.

Evolocumab and Antihypertensives

Many ASCVD patients take ACE inhibitors, ARBs, calcium channel blockers, or beta-blockers alongside evolocumab.

Mechanistic Assessment

Amlodipine (CYP3A4 substrate), lisinopril (renally cleared), losartan (CYP2C9/CYP3A4 substrate), and metoprolol (CYP2D6 substrate) all follow metabolic pathways that evolocumab cannot influence. Population PK analyses included patients on these agents and found no effect on evolocumab clearance or efficacy [3].

Blood Pressure Effects

Evolocumab does not lower or raise blood pressure. In FOURIER, systolic and diastolic BP were balanced between treatment arms at baseline and throughout follow-up [1]. No dose modifications to antihypertensives are needed when starting or stopping evolocumab.

Evolocumab and Antidiabetic Agents

Type 2 diabetes is present in roughly 37% of patients with established ASCVD. In the FOURIER diabetic subgroup analysis (N=11,031), evolocumab reduced cardiovascular events by 17% (HR 0.83, 95% CI 0.75-0.93) without worsening glycemic control [9].

Metformin, Sulfonylureas, and Insulin

Metformin is renally cleared. Sulfonylureas are CYP2C9 substrates. Insulin is a peptide hormone degraded by insulinase. None of these pathways overlap with IgG2 catabolism. No dose adjustments are required [2].

SGLT2 Inhibitors and GLP-1 Receptor Agonists

Empagliflozin, dapagliflozin, semaglutide, and liraglutide are increasingly co-prescribed with PCSK9 inhibitors in cardiometabolic patients. No interaction signals have emerged from clinical trials or post-marketing surveillance. The 2022 AHA/ACC multisociety guideline on LDL management does not list any antidiabetic contraindication for PCSK9 inhibitor use [10].

Evolocumab and Immunosuppressants

Post-transplant patients frequently develop dyslipidemia. Cyclosporine, tacrolimus, and mycophenolate are narrow-therapeutic-index drugs metabolized by CYP3A4 (cyclosporine, tacrolimus) or glucuronidation (mycophenolate).

Available Data

A small prospective study of 15 heart transplant recipients on evolocumab plus cyclosporine-based immunosuppression showed a 54% LDL-C reduction at 24 weeks with no change in cyclosporine trough levels or renal function [11]. The sample size is small, but the mechanistic prediction (no interaction) was confirmed.

Sirolimus and Everolimus

MTOR inhibitors cause hyperlipidemia in up to 75% of transplant recipients. Evolocumab could theoretically address this, but clinical data remain limited to case series. No PK interaction is expected; both mTOR inhibitors are CYP3A4 substrates, and evolocumab does not affect CYP3A4 activity [2].

Immunogenicity: Not a Drug Interaction, But Clinically Relevant

Anti-drug antibodies (ADAs) can reduce monoclonal antibody efficacy. In the FOURIER trial, binding antibodies developed in 0.3% of evolocumab-treated patients. Neutralizing antibodies were detected in 0.0%. No patient with binding antibodies showed reduced LDL-C lowering or increased adverse events [1].

Concomitant Immunomodulators

Methotrexate and other immunosuppressants reduce ADA formation with some biologics (e.g., adalimumab in rheumatoid arthritis). For evolocumab, the ADA rate is already near zero, so concomitant immunosuppression provides no additional benefit from an immunogenicity standpoint [12].

Injection Site Reactions

The most common adverse event with evolocumab is injection site reaction, reported in 5.7% of patients vs. 4.2% on placebo in pooled Phase III data [2]. These reactions do not increase with any co-administered drug class.

Drugs That Affect PCSK9 Levels: Indirect Interactions

While evolocumab has no direct PK drug interactions, several drugs alter circulating PCSK9 concentrations, which could theoretically modify evolocumab's pharmacodynamic response.

Statins Increase PCSK9

Statin therapy increases hepatic PCSK9 mRNA expression by 30% to 200% depending on dose and intensity [4]. Higher circulating PCSK9 means more target for evolocumab to neutralize. At therapeutic doses (140 mg Q2W or 420 mg QM), evolocumab provides sufficient antibody to suppress free PCSK9 below the limit of quantification, regardless of statin-induced PCSK9 elevation [3].

Fibrates and PCSK9

Fenofibrate may modestly increase PCSK9 levels through PPAR-alpha activation, though data are inconsistent across studies [13]. This potential increase is quantitatively small compared with statin-induced PCSK9 elevation and is unlikely to affect evolocumab efficacy at standard doses.

Berberine and Nutraceuticals

Berberine has been reported to lower PCSK9 mRNA in hepatocytes via an SREBP-2 independent mechanism [14]. Whether this translates into a clinically meaningful change in evolocumab response is unknown. No clinical trials have studied the combination.

Special Populations and Interaction Considerations

Hepatic Impairment

Evolocumab pharmacokinetics are unchanged in mild hepatic impairment (Child-Pugh A). Patients with moderate-to-severe hepatic impairment (Child-Pugh B or C) were excluded from clinical trials, so data are absent rather than negative [2]. In these patients, reduced hepatic LDL receptor expression could theoretically limit evolocumab's efficacy, but this is a pharmacodynamic concern rather than a drug interaction.

Renal Impairment

Population PK analysis showed no effect of mild-to-moderate renal impairment on evolocumab clearance [3]. This is expected: monoclonal antibodies are too large (144 kDa) for glomerular filtration. No dose adjustment is needed for renal impairment at any stage, including dialysis patients.

Elderly Patients

In FOURIER, 7,390 patients were aged 65 or older. Evolocumab efficacy and safety, including the absence of drug-drug interactions, were consistent across age subgroups [1]. Age-related polypharmacy does not create new interaction risks specific to evolocumab.

Comparison With Alirocumab (Praluent): Interaction Profiles

Alirocumab, the other FDA-approved PCSK9 inhibitor, shares evolocumab's monoclonal antibody structure and proteolytic clearance pathway. Its drug interaction profile is equally clean [15]. The choice between evolocumab and alirocumab is driven by dosing preference, formulary status, and cardiovascular outcome trial data (FOURIER for evolocumab, ODYSSEY OUTCOMES for alirocumab), not by interaction differences.

Inclisiran (Leqvio): A Mechanistically Different PCSK9 Approach

Inclisiran is a small interfering RNA (siRNA) that silences hepatic PCSK9 mRNA. Unlike evolocumab, inclisiran is partially metabolized by nucleases and may interact with hepatic uptake transporters (ASGPR-mediated endocytosis). Early data suggest no CYP-mediated interactions, but the pharmacokinetic profile differs fundamentally from monoclonal antibodies [16]. Patients switching from evolocumab to inclisiran should not assume identical interaction safety.

Summary of Interaction Risk by Drug Class

| Co-Administered Drug | Interaction Type | Clinical Action | |---|---|---| | Statins (any) | Beneficial PD combination | No dose adjustment | | Ezetimibe | No PK overlap | No dose adjustment | | Warfarin | No CYP2C9 effect | Standard INR monitoring | | DOACs | No CYP3A4/P-gp effect | Standard monitoring | | ACE inhibitors / ARBs | No interaction | No dose adjustment | | Metformin | No interaction | No dose adjustment | | Insulin | No interaction | No dose adjustment | | SGLT2 inhibitors | No interaction | No dose adjustment | | GLP-1 agonists | No interaction | No dose adjustment | | Cyclosporine | No CYP3A4 effect | Monitor trough levels per protocol | | Fibrates | Modest PCSK9 increase (PD) | No dose adjustment | | Oral contraceptives | No interaction | No dose adjustment |